Trial Profile
An open-label, single center trial to evaluate the efficacy and safety of quadruple chemotherapy (zidovudine, EPIVIR [lamivudine], 1592U89 [abacavir], and 141W94 [amprenavir]) in subjects infected with HIV-1 (GW QUAD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Abacavir (Primary) ; Amprenavir (Primary) ; Lamivudine (Primary) ; Zidovudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 25 Oct 2005 New trial record.